Research and Markets (http://www.researchandmarkets.com/research/af3ce9/stem_cell_research)
has announced the addition of the "Stem
Cell Research - Market Trends, Investment Trends and Pipeline Analysis"
report to their offering.
“Stem
Cell Research - Market Trends, Investment Trends and Pipeline Analysis”
Stem Cell Research Market Trends, Investment Trends and Pipeline Analysis
High Unmet Needs Associated with Chronic Diseases Boosts Stem Cell
Research and Development
Stem cell therapies are expected to serve the unmet needs that are
associated with treatment of certain chronic diseases. In spite of
advancements in medical technology, there are very few treatment options
available in the market to cure certain cardiovascular disorders,
cancers, autoimmune and inflammatory disorders, spinal cord injury and
others. Also, most of these therapies treat the symptoms without curing
the disease. Stem cell therapies have the capacity to fill this gap of
unmet need through its novel therapeutic approach that has the ability
to cure the diseases.
High Market Potential for Stem Cell Therapies has resulted in
Establishing Strategic Partnerships between Large Pharmaceutical
Companies and Stem Cell Research Based Companies
Strategic partnerships between Pharmaceutical companies and Stem cell
research companies have given a boost to stem cell research and
development. Almost 90% of the drugs in clinical trials fail due to
factors such as lack of effectiveness and adverse side effects of the
drug. Usually animal or tumor cells are being used and this leads to
jury-rigged tests. Hence, all major pharmaceutical companies look
forward to new technologies that would increase the possibility to
launch new therapies in the market place. At present, there has been a
spur in investments from pharmaceutical companies into stem cell
research through strategic partnerships with stem cell research
companies. Major pharmaceutical companies have planned and aligned their
objectives to enter the stem cell market in the next five years.
Pharmaceutical companies are also keen to explore various methods where
stem cells could be utilized in the drug discovery process that would
accelerate the discovery of novel drug molecules.
Promising Pipeline in Phase II and Phase III has Increased the Hopes of
Commercialization of Stem Cell Therapies
The total number of stem cell clinical trials has increased tremendously
over the last few years. The number of Phase II clinical trials has
witnessed more than a 40% jump between 2005 and 2008. With more than
five ongoing Phase III trials, the market is keenly awaiting the launch
of these therapies within the next five years. The Preclinical research
and Phase I trials have also increased at a phenomenal rate. This
increase demonstrates the emerging interests in stem cell research
across the globe.